23andMe is a personal genomics and biotechnology company. The company is well known for its personalized genetic reports to individual consumers. With consent, 23andMe also leverages its array of DNA to help produce new promising drugs. Listen closely as Ian, Brett, and Ryan go through the history, financials, and future prospects of 23andMe. Enjoy the show!
Our Tuesday Not So Deep Dives are sponsored by Potential Multibaggers. Multis are looking for stocks that have the potential to go up 10x in 10 years. Check-out the service here: https://seekingalpha.com/checkout?service_id=mp_1308
Want updates on future shows and projects? Follow us on Twitter: https://twitter.com/chitchatmoney
Subscribe to 7investing with the code "CCM" and get $10 off: https://7investing.com/subscribe/aff/4/
Interested in more of Ian's work? Follow him on Twitter: https://twitter.com/IanGrayLive
Rather watch us on video? Subscribe to our YouTube channel: https://www.youtube.com/channel/UCG5Ni-SI-jyrEsoNUhqftNQ
Contact us: chitchatmoneypodcast@gmail.com
Timestamps
Company Background | (3:53)
Industry | (8:00)
Management & Ownership | (9:44)
Valuation | (12:32)
Earnings | (13:41)
Balance Sheet | (16:30)
Our Analysis | (18:30)
Disclosure: Chit Chat Money hosts and guests are not financial advisors, and nothing they say on this show is formal advice or a recommendation. Brett Schafer and Ryan Henderson are general partners and portfolio managers at Arch Capital. Arch Capital and its partners may hold securities discussed on this show.
Learn more about your ad choices. Visit megaphone.fm/adchoices